- Acumen Powered by Robins Kaplan LLP™
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Disputes
-
June 16, 2021Robins Kaplan Receives High Ranks from Managing Intellectual Property Magazine in 2021; Six Partners Recognized as “IP Stars”
-
June 8. 2021Robins Kaplan Attorneys Named To 2021 “Southern California Rising Stars” List
-
June 7, 2021Robins Kaplan Welcomes Seasoned Insurance Litigator
-
June 28, 2021Pride Month CLE
-
September 23, 202119th Annual Golf Tournamet
-
October 7, 2021New York Women in Antitrust Group Spotlight Series
-
June 8, 2021Written Description in the Life Sciences: The Devil is in the Details
-
Spring 2021Summary of the United States Senate Subcommittee on Competition Policy, Antitrust, and Consumer Rights Hearing, Antitrust Applied
-
Spring 2021Duty to Third Parties: Focus on Foreseeability
-
June 17, 2021Financial Daily Dose 6.17.2021 | Top Story: Fed Speeds Up Timetable for Rate Hikes Based on Stronger Economic Outlook
-
June 16, 2021Financial Daily Dose 6.16.2021 | Top Story: Big Tech Critic and Antitrust Scholar Khan Named New FTC Chair
-
June 15, 2021Financial Daily Dose 6.15.2021 | Top Story: Troubled E-Truck Start-up Lordstown Motors’ CEO and CFO Resign After Board Investigation
Find additional firm contact information for press inquiries.
Read our attorneys' take on the latest news and trends in the legal and business industries.
Generics Need Sword, Shield For 'Exceptional' Patent Case
Strategies for generic drug companies to avoid paying exceptional-case attorney fees and costs in patent litigation with brand holder.
September 18, 2014
Generic drug companies marketing in the U.S. have particularly rough going these days. The year 2013 saw substantial new Generic Drug User Fee Amendments "user fees" levied on generics for access to the U.S.Food and Drug Administration. The same year brought the U.S. Supreme Court’s Actavis decision: Now the Federal Trade Commission can sue generics for structuring pharma litigation settlements such that the generic company receives something of value from the brand.
All Content © 2003‐2014, Portfolio Media, Inc.
The articles on our website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice. The views and opinions expressed in this article are those of the author(s) and do not necessarily reflect the views or official position of Robins Kaplan LLP.
Law360
READ FULL ARTICLE Related Professionals
Jeffrey Alan Hovden
Partner
Related Publications
June 8, 2021
Written Description in the Life Sciences: The Devil is in the Details
Sharon Roberg-Perez, William Jones - IPWatchdog
May 5, 2021
Bio-Rad Ruling Highlights IP Assignment Clause Limits
Bryan J. Vogel, Derrick J. Carman - Law360
April 20, 2021
Copyright Concerns For NFT Buyers, Sellers In Music Industry
Carly Kessler - Law360
First Quarter
ANDA Approvals
GENERICally Speaking Spring 2021
First Quarter
ANDA Litigation Settlements
GENERICally Speaking Spring 2021
Related News
June 16, 2021
May 20, 2021
April 21, 2021
March 1, 2021
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.